Sanofi

Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.

Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.

Regeneron reported strong Q1 results with revenue up 19% and earnings above estimates, but Eylea sales declined and an FDA delay on a new syringe manufacturer weighs on shares.

Pfizer shares declined 1.6% on Thursday, caught in a broad market downturn. The company navigates falling COVID product revenue while advancing its pipeline, including a new weight-loss drug approval in China.

Pfizer shares declined slightly as regulatory scrutiny of mRNA vaccines eased, offset by positive mid-stage trial results for its experimental eczema drug tilrekimig.

Pfizer announced its experimental eczema drug tilrekimig achieved its main goal in a mid-stage study, showing significant symptom improvement. The company plans to initiate a pivotal Phase 3 trial later this year.